These tumor antigenic peptides can be exploited for personalized vaccines, expansion of antitumor CD8+ T cells for adaptive cell therapy and for the development of chimeric antigen-receptor-bearing T cells [10,11]. This evidence concerns the gene CD8A and neoplasm.